{"id":"als-008176","_chembl":{"chemblId":"CHEMBL3417258","moleculeType":"Small molecule","molecularWeight":"433.86"},"modality":"Small molecule","_dailymed":null,"mechanism":{"target":"RSV RNA-dependent RNA polymerase (RdRp)","explanation":"ALS-008176 is converted to its active triphosphate form inside cells, where it acts as a nucleoside analog inhibitor of the respiratory syncytial virus RNA polymerase. By interfering with viral RNA synthesis, it prevents RSV replication and reduces viral load in infected patients.","oneSentence":"ALS-008176 is a nucleoside analog prodrug that inhibits RSV RNA polymerase, blocking viral replication."},"_scrapedAt":"2026-03-28T04:08:24.897Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_claudeStub":{"ts":1779123530,"model":"claude-sonnet-4-5-20250929"},"competitors":[{"name":"ribavirin","brand":"Virazole","company":null,"rationale":"Nucleoside analog antiviral used for severe RSV infections"},{"name":"palivizumab","brand":"Synagis","company":"AstraZeneca","rationale":"Monoclonal antibody for RSV prophylaxis in high-risk infants"},{"name":"presatovir","brand":null,"company":"Gilead Sciences","rationale":"Investigational RSV fusion inhibitor for treatment"}],"description":"ALS-008176 is an investigational antiviral compound developed by Alios BioPharma for the treatment of respiratory syncytial virus (RSV) infection. The drug was evaluated in clinical trials as a potential oral therapy for RSV but development was discontinued following Phase 2 studies.","indications":{"approved":[{"status":"investigational","condition":"Respiratory syncytial virus (RSV) infection","patientPopulation":"Adult patients with RSV infection"}]},"trialDetails":[{"nctId":"NCT02673476","phase":"PHASE2","title":"A Phase 2a Study to Evaluate Orally Administered ALS-008176 in Adults Hospitalized With a Respiratory Syncytial Virus","status":"COMPLETED","sponsor":"Alios Biopharma Inc.","startDate":"2016-02-29","conditions":"Respiratory Syncytial Virus Infections","enrollment":9},{"nctId":"NCT03010059","phase":"PHASE1","title":"A Study to Assess the Relative Bioavailability of JNJ64041575 Administered as 2 Different New Concept Formulations (Oral Suspension and Tablet) Compared to Their Respective Current Formulations, and to Assess the Effect of Food on the Pharmacokinetics of the 2 New Concept Formulations","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2017-02-06","conditions":"Healthy","enrollment":48},{"nctId":"NCT02813460","phase":"PHASE1","title":"Study to Assess the Taste Profile of Different ALS-008176 Oral Liquid Formulations in Healthy Adult Participants","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2016-06","conditions":"Healthy","enrollment":11},{"nctId":"NCT02833831","phase":"PHASE1","title":"Study to Evaluate the Effect of ALS-008176 on Cardiac Repolarization Interval in Healthy Participants","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2016-06-02","conditions":"Healthy","enrollment":103},{"nctId":"NCT02202356","phase":"PHASE1","title":"A Study of ALS-008176 in Infants Hospitalized With RSV","status":"COMPLETED","sponsor":"Alios Biopharma Inc.","startDate":"2014-07-23","conditions":"Respiratory Syncytial Virus Infections","enrollment":183},{"nctId":"NCT03189498","phase":"PHASE1","title":"A Study to Evaluate the Effect of Renal Impairment on the Pharmacokinetics of JNJ-64041575 in Adult Participants With Various Degrees of Renal Function","status":"COMPLETED","sponsor":"Janssen Pharmaceutica N.V., Belgium","startDate":"2017-07-11","conditions":"Renal Insufficiency","enrollment":38},{"nctId":"NCT02094365","phase":"PHASE2","title":"A Phase 2a Study to Evaluate ALS-008176 in the Virus Challenge Model","status":"COMPLETED","sponsor":"Alios Biopharma Inc.","startDate":"2014-03","conditions":"Respiratory Syncytial Virus Infections","enrollment":62},{"nctId":"NCT02935673","phase":"PHASE2","title":"Study to Evaluate the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of Orally Administered Lumicitabine Regimens in Adult Participants Hospitalized With Respiratory Syncytial Virus","status":"TERMINATED","sponsor":"Janssen Research & Development, LLC","startDate":"2016-10-25","conditions":"Respiratory Syncytial Viruses","enrollment":49},{"nctId":"NCT03333317","phase":"PHASE2","title":"A Study to Evaluate the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of Orally Administered Lumicitabine (JNJ-64041575) Regimens in Hospitalized Infants and Children Aged 28 Days to 36 Months Infected With Respiratory Syncytial Virus","status":"TERMINATED","sponsor":"Janssen Research & Development, LLC","startDate":"2017-11-24","conditions":"Respiratory Syncytial Viruses","enrollment":7},{"nctId":"NCT03502694","phase":"PHASE2","title":"Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of Oral Lumicitabine Regimens in Hospitalized Adult Participants Infected With Human Metapneumovirus","status":"WITHDRAWN","sponsor":"Janssen Research & Development, LLC","startDate":"2018-11-05","conditions":"Metapneumovirus","enrollment":""},{"nctId":"NCT03468777","phase":"PHASE1","title":"A Crossover Study to Assess the Drug-drug Interaction of Acid Reducing Agent(s) on the Pharmacokinetics of a Single Oral Dose of Lumicitabine (JNJ-64041575) in Healthy Adult Participants","status":"TERMINATED","sponsor":"Janssen Research & Development, LLC","startDate":"2018-03-06","conditions":"Healthy","enrollment":18},{"nctId":"NCT03441529","phase":"PHASE1","title":"A Crossover Study to Assess the Effect of Intravenous Infusion of Piperacillin/Tazobactam on the Pharmacokinetics of Orally Administered Lumicitabine (JNJ-64041575) in Healthy Adult Participants","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2018-02-09","conditions":"Healthy","enrollment":18},{"nctId":"NCT01906164","phase":"PHASE1","title":"Study of Single and Multiple Doses of ALS-008176 in Healthy Volunteers","status":"COMPLETED","sponsor":"Alios Biopharma Inc.","startDate":"2013-05-31","conditions":"Respiratory Syncytial Virus Infections","enrollment":101},{"nctId":"NCT02231671","phase":"PHASE1","title":"A Phase 1, Open-Label Study of the Absorption, Metabolism, Excretion and Absolute Bioavailability of ALS-008176","status":"COMPLETED","sponsor":"Alios Biopharma Inc.","startDate":"2014-08-31","conditions":"Respiratory Syncytial Virus Infections","enrollment":12},{"nctId":"NCT02478333","phase":"PHASE1","title":"A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of ALS-008176 in Healthy Japanese Adult Participants","status":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","startDate":"2015-05","conditions":"Respiratory Syncytial Virus Infections","enrollment":24}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"ALS-008176","genericName":"ALS-008176","companyName":"Alios Biopharma Inc.","companyId":"alios-biopharma-inc","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":5,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}